Application of immortalized human erythroid progenitor cell line in serologic tests to detect red blood cell alloantibodies

Abstract

Application of erythroid progenitor cell lines for screening for unexpected antibodies could be helpful in solving issues such as reagent availability associated with the conventional RBC-based assay. The genetic expandability of erythroid progenitor cell lines by gene modification techniques could lead to the development of more convenient reagent RBCs.

Comparison of the programmed freezer method and deep freezer method in the manufacturing of frozen red blood cell products

“…Product supernatants were obtained by centrifugation at 1710g for 10 min at 4°C twice to measure either Hb or K + concentrations. Hb concentration was quantified using the leukocrystal violet method [14, 15] as described previously, and K + concentration was measured at 22°C on a blood gas and electrolyte analyser (Cobas b 221; Roche Diagnostics, Ltd., Mannheim, Germany).…”

Clinical applications of CRISPR‐based genome editing and diagnostics

“…Similarly, customized platelets with rare alloantigenic epitopes (HPA‐1b) have been generated by editing induced pluripotent stem cells and megakaryocyte‐like cells, offering future diagnostic and therapeutic applications for thrombocytopenia . Further, studies suggest that engineering induced pluripotent stem cells into reagent red cells with rare antigen phenotypes show promise for alleviating a great shortage of diagnostic cells for patients with complex alloantibody profiles . The field is rapidly addressing challenges associated with differentiation, enucleation, and scalability to make genome‐edited, customized blood cells a reality in transfusion medicine …”

“…94 Further, studies suggest that engineering induced pluripotent stem cells into reagent red cells with rare antigen phenotypes show promise for alleviating a great shortage of diagnostic cells for patients with complex alloantibody profiles. 95 The field is rapidly addressing challenges associated with differentiation, enucleation, and scalability to make genome-edited, customized blood cells a reality in transfusion medicine. 96 The progress made in ex vivo CRISPR therapeutics will hopefully translate to in vivo-compatible administration of genome-editing platforms for a wide variety of diseases.…”

Generation of ‘designer erythroblasts’ lacking one or more blood group systems from CRISPR/Cas9 gene‐edited human‐induced pluripotent stem cells

“…Given the current constraints, blood donors are a finite resource for such cells. 9,10 As a means to address these problems, we have created 'designer erythroblasts' with custom phenotypes from a human induced pluripotent stem cell (hiPSC) line. 11 The hiPSC were chosen as source material because they provide an infinite source of hematopoietic progenitor cells (HPCs), and upon further differentiation, RBCs.…”